Sensex
83,938.71 profit arw -465.75 (-0.55%)
Nifty
25,722.10 profit arw -155.75 (-0.60%)
Nasdaq
18,355.20 profit arw -497.09 (-2.64%)
logo img

GET IN TOUCH

GET IN TOUCH

Refresh Captcha
Equity

As on : 30-Oct-2025
Hot Pursuit
30-Oct-2025     08:31

Zydus Lifesciences receives USFDA EIR for Baddi facility

The inspection at the facility was conducted by the USFDA from 4 August to 13 August 2025. Following the review, the agency has classified the facility as Voluntary Action Indicated (VAI), and the inspection has been concluded as closed by the USFDA.

The EIR has classified the facility as Voluntary Action Indicated (VAI). The USFDA has concluded this inspection as closed.

Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The company's consolidated net profit rose 3.3% to Rs 1,466.80 crore on a 7% rise in revenue from operations to Rs 6,467 crore in Q1 FY26 over Q1 FY25.

The counter rose 0.04% to Rs 1,001.80 on the BSE.

Powered by Capital Market - Live News

INDIAN INDICES

Sensex

83,938.71 -465.75 (-0.55%)

Nifty

25,722.10 -155.75 (-0.60%)

GLOBAL INDICES

USD

NA

NASDAQ
HANG SENG

25,906.65 -376.05(-1.43%)